Research & Development World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Imaging
    • Nanotechnology
    • Semiconductors
  • Controlled Environments
    • Cleanrooms
    • Graphene
    • Lasers
    • Regulations/Standards
    • Sensors
  • Scientific Computing
    • Big Data
    • HPC/Supercomputing
    • Informatics
    • Security
    • Software
  • R&D 100 Awards
    • ENTER NOW
    • 2020 Winners
    • Winner Archive
    • R&D 100 Conference
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • 2021 Funding Forecast
  • COVID-19

Vaccines Not Protecting Farmed Fish From Disease

By University of Waterloo | January 22, 2018

The vaccines used by commercial fish farmers are not protecting fish from disease, according to a new study.

The study was compiled by researchers at the University of Waterloo, the Pontifical Catholic University of Valparaiso and Chile’s University of Valparaiso. It showed vaccinated fish tend to show more symptoms when contracting diseases, with the health impacts and ultimately deaths occurring as if they’d never received a vaccine.

“Today’s vaccines are marketed to fish farms as necessary disease prevention and are even required by some insurance companies, but they are not nearly as effective as needed under real world conditions.” said Brian Dixon, a professor in biology at Waterloo. “Some operators are giving five vaccinations per fish and then there are fish losses from the stress of receiving multiple handlings and injections.”

In the study, the researchers tested the efficacy of the vaccine for the bacterial pathogen Piscirickettsia salmonis by comparing the reaction of vaccinated and non-vaccinated Atlantic salmon when exposed to the sea louse Caligus rogercresseyi in the lab.

They found that although the number of bacteria living inside the fish was much lower in vaccinated fish, they showed many more signs of infection and a higher death rate compared with the unvaccinated group upon exposure to the sea lice.

The study concluded that once vaccinated, the salmon was unable to fight off multiple diseases at once. It’s first study showing how a parasite in fish can override the protective effects of a vaccine for another disease.

The experience of salmon farmers in Chile supports this finding, where salmon are raised largely in open cages off the coast, exposing them to variety of pathogens, the most common of which is sea lice.

The researchers say this highlights the need for veterinary pharmaceutical companies to change how they design and test vaccines in the first place, recognizing how different fish immune systems are from the current human model.

“Fish have a limited number of resources to respond to an illness so their immune system makes choices–when they’re infected by sea lice, for example, the fish’s immune system is suddenly geared to respond to that specific threat, leaving them totally exposed to other threats like P. salmonis,” said Dixon, a Canada Research Chair in Fish and Environmental Immunology. “It’s like sending ambulances out to all emergencies when in fact some of those emergencies need firefighters.”

In the 2008 Chile’s farmed salmon industry was nearly wiped out by Infectious Salmon Anaemia Virus (ISVA). Since then salmon farmers have been turning to vaccines to lower their use of antibiotics while prevent devastating losses from reoccurring disease. But vaccinations are expensive and can cost Chilean operators as much as 30 per cent of cost of raising each fish.

Related Articles Read More >

French and Swiss scientists demonstrate ‘all-in-one’ technique that could accelerate phage-therapy diagnosis
The need for next generation analytics to extract valuable insights from genomic biobank data
Reusable respirator could ease COVID-19 medical mask shortages
Euroimmun launches SARS-CoV-2 NeutraLISA assay to determine the neutralizing capacity of anti-SARS-CoV-2 antibodies

Need R&D World news in a minute?

We Deliver!
R&D World Enewsletters get you caught up on all the mission critical news you need in research and development. Sign up today.
Enews Signup
Tweets by @RandDWorld

R&D World Digital Issues

February 2020 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R& magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • 2021 Global Funding Forecast

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Imaging
    • Nanotechnology
    • Semiconductors
  • Controlled Environments
    • Cleanrooms
    • Graphene
    • Lasers
    • Regulations/Standards
    • Sensors
  • Scientific Computing
    • Big Data
    • HPC/Supercomputing
    • Informatics
    • Security
    • Software
  • R&D 100 Awards
    • ENTER NOW
    • 2020 Winners
    • Winner Archive
    • R&D 100 Conference
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • 2021 Funding Forecast
  • COVID-19